Sangamo Therapeutics, Inc. reported impairment charges for the first quarter ended March 31, 2024. For the quarter, the company reported impairment of long-lived assets of $4,349,000 compared to $20,433,000 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4548 USD | +3.74% |
|
+41.02% | -16.29% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.29% | 94.38M | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- SGMO Stock
- News Sangamo Therapeutics, Inc.
- Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024